𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The effects of local and systemic alendronate delivery on wear debris-induced osteolysis in vivo

✍ Scribed by Fang-Bing Zhu; Xun-Zi Cai; Shi-Gui Yan; Han-Xiao Zhu; Rui Li


Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
434 KB
Volume
28
Category
Article
ISSN
0736-0266

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

We investigated the effects of locally and systemically administered alendronate on wear debris‐induced osteolysis in vivo. Endotoxin‐free titanium particles were injected into rabbit femurs, prior to insertion of a nonweight‐bearing polymethylmethacrylate plug into the distal femur canal. Then the particles were repeatedly injected into the knee 2, 4, and 6 weeks after the implantation. Alendronate was incorporated at three different concentrations (0.1, 0.5, and 1.0 wt %) into bone cement for local delivery. For systemic delivery, alendronate was subcutaneously injected (1.0 mg/kg/week) 1 week after the implantation and then once a week until sacrifice. Eight weeks postoperatively, there was significant evidence of osteolysis surrounding the plug in the control group compared with markedly blocked osteolysis in the 0.5 wt % and the 1.0 wt % groups, and the systemic group. There was a concentration‐dependent effect of alendronate‐loaded bone cement on the improvement of peri‐prosthetic bone stock. Notably, no significant differences were found between the 0.5 wt % and the systemic group in peri‐prosthetic bone stock and implant fixation. Collectively, although the biological efficacy after the systemic delivery of alendronate was slightly higher than that in the local treatment groups, alendronate‐loaded bone cement may be therapeutically effective in inhibiting titanium particle‐induced osteolysis in vivo. © 2010 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 28:893–899, 2010


📜 SIMILAR VOLUMES


Sulbactam-cefoperazone polyhydroxybutyra
✍ Yagmurlu, M. Firat ;Korkusuz, Feza ;G�rsel, Ihsan ;Korkusuz, Petek ;�rs, �lken ; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 492 KB

In this study, a novel antibiotic carrier system for use in the treatment of implant-related and chronic osteomyelitis was developed. Sulbactam-cefoperazone was introduced to rods of polyhydroxybutyrate-co-hydroxyvalerate (22 mol % HV, w/w), a member of a family of microbialorigin polymer that is bi